DJIA 18,132.70 -81.72 -0.45%
NASDAQ 4,963.53 -24.36 -0.49%
S&P 500 2,104.50 -6.24 -0.30%
market minute promo

EnteroMedics (NASDAQ: ETRM)

1.06 -0.02 (-1.85%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

ETRM $1.06 -1.85%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $1.10
Previous Close $1.08
Daily Range $1.05 - $1.10
52-Week Range $0.99 - $2.65
Market Cap $73.3M
P/E Ratio -2.77
Dividend (Yield) $0.00 (0.0%)
Volume 307,527
Average Daily Volume 1,772,298
Current FY EPS -$0.39




Healthcare IT

EnteroMedics (ETRM) Description

A development stage medical device company focused on the design and development of devices that use neuroblocking technology to treat obesity its associated co-morbidities and other gastrointestinal disorders. Website:

News & Commentary

Despite the CDC's Best Efforts, This Disease Just Hit Record Levels

The CDC is doing its best to curb this disease, but a recent Gallup survey suggests that more people have this disease than ever before!

Canaccord Genuity Remains Bullish on EnteroMedics Following Q4 Earnings

EnteroMedics' (ETRM) CEO Mark Knudson on Q4 2014 Results -- Earnings Call Transcript

Gallup Says Obesity Rates Climb Again - Can Anti-Obesity Companies Cash In?

Newly Approved Weight Loss Method Works by Tricking Your Brain

What's the best way to lose weight? One company thinks it's simple: don't get hungry.

Biotech Stock Mailbag: Arena Pharma, Agenus, EnteroMedics

Top-Rated Stock Picks and Most-Read Stories at Jan. 11-17, 2015

Forget Pills! Could This Device Put an End to Obesity in America?

We've witnessed three oral anti-obesity meds approved since mid-2012, but this newly approved device could be a game-changer.

Seeking Alpha's Biotech Weekly: Roche Takes Control, Shire's A Buyer, And More

Enteromedics Garners FDA Approval For Obesity Device: What's Next

See More ETRM News...

ETRM's Top Competitors

ETRM $1.06 (-1.85%)
Current stock: ETRM
$0.00 (0.00%)
Current stock:
MDT $77.59 (-1.55%)
Current stock: MDT
COV $108.06 (0.00%)
Current stock: COV